Abeona Therapeutics Inc. (ABEO)

Abeona Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	71.18	-63.73	-54.19	-39.7	-84.94
Depreciation & Amortization	2.55	2	2.29	3.09	3.25
Stock-Based Compensation	10.78	6.63	4.77	3.05	8.92
Other Adjustments	-155.45	3.47	11.91	-4.04	25.37
Change in Receivables	-5.06	0.79	-2.04	2.81	-3
Changes in Inventories	-5.49	-	-	-	-
Changes in Accounts Payable	6.54	1.51	2.04	-4.11	0.83
Changes in Income Taxes Payable	0.13	-	-	-	-
Changes in Other Operating Activities	-1.5	-6.68	-1.79	-4.6	-16.09
Operating Cash Flow	-76.33	-56.02	-37.01	-43.48	-65.67
Capital Expenditures	-7.98	-2.45	-0.33	-0.13	-4.15
Sale of Property, Plant & Equipment	-	0.02	0.2	1.73	-
Purchases of Investments	-206.63	-157.01	-51.64	-78.21	-20.16
Proceeds from Sale of Investments	167.27	120.2	51.97	52.64	90.38
Other Investing Activities	152.37	-	-	-	-
Investing Cash Flow	105.03	-39.24	0.21	-23.96	66.06
Long-Term Debt Issued	-	20	-	-	-
Net Long-Term Debt Issued (Repaid)	-	20	-	-	-
Issuance of Common Stock	26.08	85.63	37.39	46.96	24.86
Repurchase of Common Stock	-0.04	-0.53	-0.18	-0.01	-
Net Common Stock Issued (Repurchased)	26.04	85.1	37.21	46.96	24.86
Issuance of Preferred Stock	-	-	-	22.47	-
Repurchase of Preferred Stock	-	-	-	-26.25	-
Net Preferred Stock Issued (Repurchased)	-	-	-	-3.78	-
Other Financing Activities	-	-0.96	-0.15	-	-
Financing Cash Flow	26.04	104.14	37.06	43.17	24.86
Net Cash Flow	54.74	8.88	0.26	-24.27	25.26
Free Cash Flow	-84.3	-58.46	-37.34	-43.61	-69.82
FCF Margin	-1448.47%	-	-1066.86%	-3084.37%	-2327.20%
Free Cash Flow Per Share	-1.27	-1.42	-1.75	-5.55	-17.73
Levered Free Cash Flow	65.43	-49.35	-51.98	-49.22	-101.1
Unlevered Free Cash Flow	-95.07	-69.83	-44.93	-56.66	-106

Updated Mar 17, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q